Company news

Editas Medicine, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

June 6, 2022

Editas Medicine Reports Inducement Grants to New Chief Executive Officer

June 5, 2022

Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting

May 17, 2022

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

May 11, 2022

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference

May 3, 2022

Editas Medicine Announces First Quarter 2022 Results and Business Updates

May 3, 2022

Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting

May 1, 2022

Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update

April 26, 2022

Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia

April 25, 2022

Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer

April 13, 2022

Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

April 10, 2022

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

April 7, 2022

Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

February 27, 2022

Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates

February 23, 2022

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update

February 15, 2022

Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

January 9, 2022

Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

December 19, 2021

Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

December 11, 2021

Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting

November 11, 2021

Editas Medicine Announces Third Quarter 2021 Results and Business Updates

November 7, 2021

Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition

November 3, 2021

Editas Medicine Names Bernadette Connaughton to Board of Directors

October 27, 2021

Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update

October 24, 2021

Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress

October 19, 2021

Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting

October 6, 2021

Editas Medicine to Present at Chardan’s 5th Annual Genetic Medicines Conference

September 29, 2021

Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10

September 28, 2021

Editas Medicine Names Emma Reeve to Board of Directors

September 7, 2021

Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September

September 6, 2021

Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting

August 19, 2021

Editas Medicine Announces Second Quarter 2021 Results and Business Updates

August 3, 2021

Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell Medicines

July 28, 2021

Editas Medicine to Host Conference Call Discussing Second Quarter 2021 Results and Corporate Update

July 27, 2021

Editas Medicine Names Bruce E. Eaton, Ph.D., as Executive Vice President and Chief Business Officer

July 25, 2021

Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement

June 22, 2021

Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer

June 14, 2021

Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth

June 13, 2021

Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress

June 10, 2021

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer

May 4, 2021

Editas Medicine Announces First Quarter 2021 Results and Update

May 4, 2021

Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting

May 3, 2021

Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting

April 30, 2021

Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update

April 27, 2021

Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update

February 24, 2021

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update

February 17, 2021

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

February 7, 2021

Editas Medicine Announces Transition of Chief Scientific Officer

January 10, 2021

Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial

January 10, 2021

Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 3, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 25 decks. Every deck is listed under its year.